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AbstrACt
Introduction Atopic dermatitis/eczema affects around 
20% of children and is characterised by inflamed, dry, 
itchy skin. Guidelines recommend ‘leave- on’ emollients 
that are applied directly to the skin to add or trap moisture 
and used regularly, they can soothe, enhance the skin 
barrier and may prevent disease ‘flares’. However, the 
suitability of the many different emollients varies between 
people and there is little evidence to help prescribers and 
parents and carers decide which type to try first.
Methods and analysis Design: pragmatic, multicentre, 
individually randomised, parallel group superiority trial of 
four types of emollient (lotions, creams, gel or ointments).
Setting: general practitioner surgeries in England.
Participants: children aged over 6 months and less than 
12 years with mild- to- severe eczema and no known 
sensitivity to study emollients.
Interventions: study- approved lotion, cream, gel or 
ointment as the only leave- on emollient for 16 weeks, 
with directions to apply twice daily and as required. 
Other treatments, such as topical corticosteroids, used as 
standard care.
Follow- up: 52 weeks.
Primary outcome: validated patient- orientated eczema 
measure measured weekly for 16 weeks.
Secondary outcomes: eczema signs (Eczema Area Severity 
Index) by masked researcher, treatment use, parent 
satisfaction, adverse events, child and family quality of life 
(Atopic Dermatitis Quality of Life, Child Health Utility 9D 
and Dermatitis Family Impact).
Sample size: 520 participants (130 per group).
Analysis: intention- to- treat using linear mixed models for 
repeated measures.
Nested qualitative study: audio- recording of sample 
of baseline appointments and up to 60 interviews 
with participants at 4 and 16 weeks, interviews to be 
transcribed and analysed thematically.
Ethics and dissemination Ethics approval granted by 
the NHS REC (South West - Central Bristol Research Ethics 
Committee 17/SW/0089). Findings will be presented at 
conferences, published in open- access peer- reviewed 
journals and the study website; and summaries shared 
with key stakeholders.
trial registration number ISRCTN84540529
IntroduCtIon
background and rationale
Eczema affects around 20% of children.1 It is 
characterised by dry and inflamed itchy skin, 
and it can have a significant impact on the 
quality of life for both the child and their 
family.2 In accordance with the recommended 
strength and limitations of this study
 ► First, adequately powered head- to- head pragmatic 
trial of the four main types of emollient prescribed 
for the treatment of eczema in children, recruited 
from primary care, with long- term follow- up.
 ► The primary core outcome is a validated patient- 
reported measure (POEM) that captures symptoms 
of eczema that matter to patients, and weekly mea-
sures over the 16 weeks mean that all participants 
who complete at least one POEM post- baseline will 
be included in the analysis. Researchers undertak-
ing assessments of eczema signs (secondary out-
come) are masked to allocation and use validated 
core outcome (Eczema Area Severity Index).
 ► Parents and their clinicians are unmasked and there-
fore their assessment of both the effectiveness and 
acceptability of the study emollient may be biased.
 ► Study emollients of each type are similar, increasing 
generalisability of the findings, but because they are 
not identical subtle differences both within- types 
and between- types may not be identified.
 ► The findings will reduce ‘trial- and- error’ prescribing 
of initial choice of emollient but should not be used 
to restrict emollient options.
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nomenclature of the World Allergy Organisation, we use 
the label ‘eczema’ to refer to the clinical phenotype of 
atopic eczema/dermatitis.3
The majority of children with eczema have disease 
of mild or moderate severity and are diagnosed and 
managed exclusively in primary care.4 Children are 
commonly prescribed a moisturiser (emollient) and 
topical corticosteroid/topical calcineurin inhibitor to use 
alongside to treat or prevent ‘flares’.5 By direct applica-
tion to the skin, emollients improve skin hydration and 
reduce symptoms such as stinging or itching, but they 
can also act as a barrier to potential irritants. Mild anti- 
inflammatory properties may reduce reliance on topical 
corticosteroids/calcineurin inhibitors.6 Many directly 
applied or ‘leave- on’ emollients can also be used as soap 
substitutes.
However, there are many different emollients avail-
able and little evidence that any one emollient is better 
than another as a leave- on treatment. The main formu-
lations are lotions, creams, gels and ointments, which 
vary in their consistency from ‘light’ to ‘heavy’. This 
mainly reflects differences in their oil (lipid) to water 
ratios. Some products also contain humectants which 
help retain moisture, but emollients containing urea or 
antimicrobial compounds tend to be reserved for more 
severe disease.
The absence of evidence regarding the comparative 
clinical and cost- effectiveness of different products is 
reflected in emollient formularies. Clinician prescribing 
in the National Health Service (NHS) is guided by locally 
produced and maintained formularies, which recommend 
which items should be prescribed in that area. In 2018, 
across England and Wales there were over 100 different 
emollient formularies which made widely varying recom-
mendations about 109 different emollients.7 The current 
situation where healthcare professionals recommend 
different emollients and carers find an effective emollient 
through a process of ‘trial and error’ is detrimental to 
both families and the NHS.8 9
In 2007, National Institute for health and Clinical 
Excellence (NICE) recommended research to identify 
‘the most effective and cost- effective combinations of 
emollient products to use for the treatment of childhood 
atopic eczema’.5 A recently published Cochrane review 
identified 77 trials, comprising 6603 participants, evalu-
ating the effectiveness of emollients.6 The authors were 
unable to conclude whether some of the moisturisers, 
or their ingredients, are better than others, and recom-
mended head- to- head comparisons in clinical trials.
Aim and objectives
The aim of the study is to compare the effectiveness and 
acceptability of four types of emollient (lotion, cream, gel 
and ointment) commonly used to treat eczema.
The objectives are to compare the four different emol-
lient types, over the medium (16 weeks) and long- term 
(52 weeks), with respect to:
 ► Parent- reported eczema symptoms.
 ► Researcher assessment of eczema signs.
 ► Quality of life for the child.
 ► Impact of eczema on the family.
 ► Adverse effects.
 ► Acceptability of and parent satisfaction with study 
emollient.
 ► Frequency and quantity of study emollient and other 
emollient use.
 ► Use of other eczema treatments (including topical 
corticosteroid and calcineurin inhibitor).
 ► Number of well- controlled weeks.
trial design
Best emollients for eczema (BEE) is a pragmatic, multi-
centre, individually randomised, parallel group supe-
riority trial of four types of emollient in children with 
eczema, with nested qualitative study.
It is a type A Clinical Trial of an Investigational Medic-
inal Product trial, which is low risk because the use of the 
medicinal product is not higher than the risk of standard 
medical care.
MEthods And AnAlysIs
study setting
Primary care (general practitioner (GP) surgeries) in and 
around Bristol, Southampton and Nottingham.
recruitment
The stages of participant recruitment are shown in 
figure 1.
We will identify children aged between 6 months and 
less than 12 years with eczema via an electronic medical 
records search. A GP or a delegated member of the 
practice team will screen the search results for inclu-
sion/exclusion criteria. Parents and carers (hereafter 
parents) of potentially eligible children will be posted 
an invitation. In addition, GPs can recruit participants 
opportunistically.
Interested parents will complete a brief screening 
questionnaire that will assess initial eligibility. Potentially 
eligible participants will be contacted by a member of 
the research team to explain more about the study and 
schedule a baseline appointment at which consent will be 
received.
Eligibility and allocation
Inclusion and exclusion criteria are summarised in the 
box 1.
Participants will be randomised in a 1:1:1:1 ratio to the 
four groups, stratified by centre and minimised by base-
line patient- orientated eczema measure (POEM — mild 
3 to 7 vs moderate/severe 8+)10 and participant age (less 
than 2 years old vs 2 years and above) using a validated 
web- based randomisation system supplied by the Bristol 
Randomised Trials Collaboration. Allocation is secure, 
concealed and cannot be changed once made.
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Figure 1 Overview of participant pathway through the 
study. GP,general practitioner.
box 1 Participant eligibility criteria
Inclusion criteria
 ► Children must:
 – be aged between 6 months and less than 12 years of age
 – have eczema diagnosed by an appropriately qualified healthcare 
professional (registered doctor, nurse or health visitor)
 – mild eczema or worse (patient- orientated eczema measure score 
>2 within previous 28 days)
 ► The person giving consent must:
 – have parental responsibility for the participant
 – be willing to use the randomly allocated emollient type as the 
only leave- on emollient for 16 weeks.
Exclusion criteria
 ► Child:
 – known sensitivity to study emollients or their constituents
 – participating in another research study currently or in the last 4 
months
 – any other known adverse medical or social circumstance that 
would make invitation to the study inappropriate (as determined 
by GP surgery)
 ► The person giving consent:
 – unable to give informed consent
 – insufficient written English to complete outcome measures
Intervention
In the NHS, GP prescribing is restricted by local formu-
laries which vary widely and change over time. Therefore, 
participants will be randomised to a type of emollient 
(lotion, cream, gel or ointment) rather than a specific 
named emollient. However, to reduce heterogeneity 
within each type of emollient, GPs will be asked to only 
prescribe emollients which share certain characteris-
tics (table 1). Study emollients will therefore be distinct 
between types and similar within each type. It would be 
considered unethical to withhold an emollient from a 
participant, and so there is no ‘control’ group.
At the baseline visit, the researcher will give parents 
simple verbal advice and a one- page summary on emol-
lient use. GPs will issue a prescription of the study emol-
lient with directions to ‘Use twice daily and as required’ 
and make it available for repeat prescription. This is 
consistent with usual care, where clinician advice usually 
does not extend beyond what is written on the prescrip-
tion, sometimes backed- up with an information leaflet. 
Parents will be contacted within 1 week of randomisation 
to ensure that they have collected and started using the 
study emollient. The amount of emollient used during 
the study will be determined by the family.
Parents will be asked to agree to use the study emollient 
as the only leave- on emollient for 16 weeks. However, if 
the family have problems with or dislike their study emol-
lient, they can stop it and seek an alternative from their 
GP. In this instance, the GP/family will be encouraged to 
try another emollient of the same type.
Clinical management of eczema will otherwise be 
as usual, with participants free to continue using or 
change other treatments. Use of other emollients as soap 
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Table 1 Rules for exclusion/inclusion of different types of emollients
Type of emollient Lotion Cream Gel Ointment
Rules/group shared 
characteristics
Exclusion Antimicrobials or urea [should be centered so crosses lotion, crea, gel and ointment columns]
Inclusion Paraffin- based [should be centered so crosses lotion, crea, gel and ointment columns]
Glycerol containing 
only
No humectant or 
lanolin
Does not contain 
povidine
No additives
Example formulary emollients 
from each group*
  
Cetraben lotion,
QV lotion and
Diprobase lotion
Diprobase cream,
Epimax cream,
Aquamax cream,
Zerobase cream and
AproDerm cream
Doublebase gel,
Isomol gel,
Zerodouble gel,
AproDerm gel and
MyriBase gel
Diprobase ointment,
Emulsifying ointment BP,
White soft/Liquid paraffin 
50/50 ointment,
Paraffin White soft ointment 
and
Paraffin Yellow soft ointment
*Membership will be monitored and may change over time, keeping within the inclusion and exclusion criteria for each group.
substitutes for washing only is permissible and will not be 
classed as contamination.
outcomes
The primary outcome is POEM, measured weekly for 16 
weeks. POEM is a patient- reported outcome that can be 
completed by proxy (carer report) and captures symptoms 
of importance to parents and patients over the previous 
week.11 It demonstrates good validity, repeatability and 
responsiveness to change.12 13 We have chosen repeated 
measures because eczema is a relapsing and remitting 
long- term condition and this approach captures effective-
ness of treatments better than comparing outcomes at a 
single time point.
Secondary outcomes include:
 ► Eczema Area Severity Index (EASI).
 ► Use of study emollient/other eczema treatments.
 ► Parent- reported satisfaction with study emollient.
 ► Adverse events: localised reactions, slips and falls.
 ► Child and family- oriented quality of life measures: 
Atopic Dermatitis Quality of Life (ADQoL)14; Derma-
titis Family Impact questionnaire (DFI)15 and Child 
Health Utility 9D (CHU- 9D).16 17
A complete schedule of data collection can be found 
in table 2. We are following- up participants for 1 year 
because eczema is a relapsing- remitting condition where 
symptoms can be seasonal and there is paucity of long- 
term outcome data in relation to emollient use in chil-
dren with eczema.
Participant timeline, data collection methods and participant 
retention
Participants will take part in the trial for 52 weeks, with 
the primary outcome collected over the first 16 weeks 
(figure 1).
Baseline data will be collected by the researcher using 
paper case report forms. Parents will be given the option 
of completing follow- up questionnaires either online or 
on paper. Parents are asked to complete weekly surveys 
for the first 16 weeks and then every 4 weeks between 
16 and 52 weeks. With consent, participants’ electronic 
medical records will be reviewed for data on prescrip-
tions, consultations and referrals.
Parents will be sent regular newsletters and receive auto-
matic emails or text reminders when their questionnaires 
are due. In recognition of their time and to encourage 
retention, parents will be offered £10 vouchers at the 
baseline and 16 weeks. We will also offer the child a small 
gift, for example, ‘bee’ toy, of about £5 in value.
Masking
Table 3 summarises who is masked to treatment alloca-
tion. Procedures to maintain masking to allocation will be 
written and followed. Researcher masking will be assessed 
using the Bang blinding index.18 Because parents, partici-
pants and treating clinicians will know the treatment allo-
cation, un- masking procedures are not required.
sample size
As we have four groups, we powered our sample size 
calculation to detect a clinically meaningful differences 
in six pairwise comparisons subsequent to a global test. 
We estimate that 416 participants (104 in each group) 
are required to detect a difference of 3.0 in POEM 
scores12 19 20 between any two groups with 90% power and 
a significance level of 0.05 (after adjustment for multiple 
pairwise comparisons). We assumed a SD of 5.5 (SD of 
4.89 observed in feasibility trial21 to allow for greater vari-
ability in the data or smaller differences to be detected. 
To allow for 20% loss to follow- up, we propose recruiting 
520 patients in total.
data management
Personal data of participants’ and their parents will 
be treated as strictly confidential and entered onto a 
secure administrative database stored on the University 
of Bristol server. Anonymised trial data will be collected 
and managed using the study’s REDCap database.22 
This system will also be used to administer online ques-
tionnaires for those who choose for online rather than 
paper questionnaires. The system incorporates data entry 
and validation rules to reduce data entry errors and 
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Table 3 Masking to treatment allocation
Individual(s) Status
Participating children, their parents and any treating 
clinician
Unmasked: The allocated emollient is prescribed by the participant’s 
GP and issued by local pharmacy as in usual care.
Clinical trials unit (CTU) database staff, trial coordinators, 
trial administrator and qualitative researcher
Unmasked: CTU staff will maintain the randomisation database. The 
trial coordinator/administrator will randomise participants and be 
the initial point of contact for all enquiries relating to issues with the 
emollients.
Qualitative team (Drs Sutton, Heawood and Banks) Unmasked: Participants will be sampled based on emollient 
allocation/use and during the interviews the qualitative researcher 
will specifically ask about the different emollient types.
Junior statistician (Ms Sanderson) Unmasked: The junior statistician was initially masked knowing 
only an anonymised code for the different treatment groups. After 
approval of the statistical analysis plan, she was unmasked to 
permit preparation and discussion of unmasked data with the data 
monitoring committee.
Trial manager and chief investigator Masked: The trial manager was masked prior to the writing of the 
statistical analysis plan but is unmasked on an individual participant 
basis, when required to undertake randomisations and deal with 
potential serious adverse events. The chief investigator will only be 
unmasked in the event of a serious adverse event.
Other trial management group members: Dr MacNeill 
(senior statistician), Dr Santer & Professor Thomas (PIs), 
Ms Barrett (pharmacist), Dr Lane & Dr Taylor (CTU), 
Professors Hay & Williams (senior researchers), Ms 
Kirsty Garfield (health economist), Dr Baxter (knowledge 
mobilisation), Mrs Roberts (PPI)
Masked: Procedures will be put in place to maintain masking both 
within and outside of project meetings.
[INstead of reseacrcjers in column to left, please put Clinical Study 
Officers] Masked: Masking of researchers undertaking baseline and 
16 week visits will be monitored by means of self- report.
GP, general practitioner; PIs, principal investigators; PPI, patient and public involvement.
management functions to facilitate auditing and data 
quality assurance.
statistical methods
The analysis and presentation of the trial data will be in 
accordance with Consolidated Standards of Reporting 
Trials guidelines.23 24 A full statistical analysis plan has 
been developed and approved by the independent stat-
istician on the study’s trial steering committee ahead of 
analysis of post- randomisation data and will be made 
available via the study website.
Baseline characteristics of patients will be compared 
between the four arms by reporting summary statistics. 
Characteristics will be reported as means and SD, medians 
and IQRs or frequencies and proportions depending on 
the nature of the data and its distribution. If baseline 
characteristics of any two treatment groups differ by more 
than 10% or 0.5 SD then the effect of this variable on 
the primary outcome will be investigated in a sensitivity 
analysis.
Primary statistical analyses between the randomised 
groups will be conducted on an intention- to- treat basis. 
For the primary outcome we will use linear mixed models 
(weekly observations, level 1; nested within participants, 
level 2) to explore whether there are differences in mean 
POEM scores between treatment groups after adjusting 
for baseline scores and all stratification and minimisation 
variables used in the randomisation. Pairwise compar-
isons will be conducted to identify which intervention 
groups differed. To account for multiple testing, we will 
use a modified alpha of 0.0083 (0.05/6 pairwise compar-
isons equivalent).
Secondary outcomes will be analysed according to 
the data type and frequency of recording. Continuous 
outcomes measured at multiple time points will be anal-
ysed similarly to the primary outcome as described above. 
Continuous outcomes measured once after randomisa-
tion — such as EASI score — will be analysed using linear 
regression adjusting for baseline values where available. 
We will consider alternative methods should assumptions 
not be met.
To assess adherence to the allocated medication, for 
each participant, we will count the number of days of 
self- reported use of the allocated type of emollient and 
express that as a proportion of the number of days for 
which non- missing emollient use data are available. 
Contamination will be assessed by calculating the propor-
tion of days (among days where non- missing emollient 
use data are available) where a non- allocated emollient 
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type was used. We are unable to prespecify what consti-
tutes ‘substantial contamination’, which may inform 
further sensitivity analyses.
Other proposed sensitivity analyses include an explo-
ration of patterns of missing data and we will consider 
possible mechanisms for this. Based on these and observed 
data, appropriate methods for imputing missing data will 
be considered in sensitivity analyses. Also, should there 
be evidence of imbalance between treatment groups 
on important baseline characteristics we will conduct a 
regression analysis of the primary outcome adjusting 
additionally for these variables.
Descriptive analysis of safety endpoints will be presented 
according to randomised group. Prespecified subgroup 
analyses will investigate whether treatment effectiveness 
is modified by the following factors measured at randomi-
sation: parent expectation, age of child at randomisation, 
disease severity and eczema diagnosis. These subgroup 
analyses will involve incorporating interaction terms with 
treatment allocation to test the null hypothesis of no vari-
ation in treatment effect across subgroups. These tests are 
likely to be underpowered, however, therefore emphasis 
will be placed on the point estimates and confidence 
intervals generated.
nested qualitative study
The aims of the qualitative study are first, to support 
and optimise participant recruitment and retention; and 
second, to complement, explain and aid understanding 
of the quantitative findings
Baseline appointment recordings
To meet the first aim, a sample of baseline appointments 
(at least one per recruiting researcher) will be audio- 
recorded and reviewed by a qualitative researcher. Using 
a structured template, the interaction will be reviewed 
to ensure key information is relayed and parent under-
standing checked. Recommendations will be feedback 
individually to the relevant researcher and collectively 
(anonymised) to other recruiting researchers and the 
trial management group. Prior to the start of the baseline 
appointment, parents will be asked to give verbal consent 
for the recording, with written consent obtained at the 
end of the appointment.
Interviews with parents and trial participants
To meet the second aim, we will interview parents and, at 
their discretion, the participating children themselves, at 
4 weeks and 16 weeks after randomisation. The design is 
cross- sectional, with different families interviewed at each 
time point. However, where particularly interesting issues 
emerge, we may speak to a family at both time points. 
Parents will indicate on the trial consent form whether 
they are willing to be approached for these.
The 4 week interviews will focus on the initial use and 
acceptability of the assigned emollient. We will conduct 
up to five interviews in each trial group (total ~20), 
purposively sampling by: recruitment centre, age of child, 
eczema severity and allocated type of emollient. We will 
include those who have stopped using the allocated treat-
ment or switched emollient.
The 16 week interviews will focus on the overall expe-
rience of using the assigned emollient, perceived effec-
tiveness, planned future use of emollients and experience 
of taking part in the trial. The sampling criteria will be 
the same as for the 4 week interviews, with the additional 
criterion of intentions regarding future emollient use. We 
expect to achieve data saturation by conducting up to 10 
interviews in each trial group (total ~40).
Interviews are expected to last between 30 to 60 min. 
Topic guides (including subtopic guide for children) will 
be used but with flexibility to allow unanticipated issues 
to emerge and be further explored in later interviews. 
Interviews will be captured using an encrypted digital 
voice recorder, transcribed and anonymised to protect 
confidentiality.
The interview data will be analysed thematically, using 
a combination of deductive and inductive coding25 and 
adapted techniques of constant comparison.26 Anal-
ysis will be led by the qualitative researcher, with input 
from the qualitative co- applicants and trial management 
group. Data management and coding will be aided by 
use of NVivo software. Data will be compared within 
and across trial group, with attention to converging and 
diverging perspectives. The themes will be written up as 
interpretive summaries with illustrative verbatim quotes 
that represent the range of expressed views.
Monitoring, safety and audit
As the randomised treatments within this study do not 
differ from common usual clinical practice, risk- based 
monitoring will be implemented in line with a risk- 
assessment. Data on adverse events will be collected by 
parent self- report. No interim analyses are planned.
An independent Data Monitoring Committee has been 
established and terms of reference have been drawn up 
and agreed. The committee will meet at least annually, 
and its role is to safeguard the interests of the trial’s partic-
ipants, potential participants, investigators and sponsor; 
to assess the safety and efficacy of the trial’s interventions, 
and to monitor the trial’s overall conduct, and protect its 
validity and credibility.
The sponsor organisation is the University of Bristol. 
Adverse event reporting will be in accordance with local 
procedures.
The trial may be prematurely discontinued due to 
lack of recruitment or by the sponsor, chief investigator, 
regulatory authority or funder based on new safety infor-
mation or for other reasons given by the trial steering 
committee or data monitoring committee, regulatory 
authority or ethics committee concerned.
Public and patient involvement
In 2013, the James Lind Alliance published the eczema 
research priorities for patients and healthcare profes-
sionals and ‘Which emollients are the most effective and 
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safe in treating eczema?’ emerged as one of the highest 
ranked uncertainties.27
Co- author AR is mother of children with eczema and 
a member of Nottingham Support Group for Carers of 
Children with Eczema. We have established a group of 
parents of children with eczema, who helped develop 
the study and want to support our ongoing work through 
meetings and email communication. A patient and public 
involvement (PPI) member sits on the trial steering 
committee. We will use the internet and social media to 
promote wider patient engagement.
PPI has helped us to frame the research question 
around, ‘Which emollient to prescribe first?’ for child-
hood eczema, acknowledging that individuals differ 
in their experiences of effectiveness and tolerability of 
different emollients. It has also gave us a clear steer that 
including a non- emollient group would be unacceptable 
to many families, favoured POEM as the primary outcome 
and highlighted how emollient use may be a ‘trade off’ 
between effectiveness and acceptability.
Ongoing PPI involvement has informed both quali-
tative and quantitative data collection and helps ensure 
that the study continues to focus on delivering clinically 
important outcomes that are meaningful to patients.28
EthICs And dIssEMInAtIon
ProtoCol AMEndMEnts
Any amendments to the protocol will be reported accord-
ingly to the regulatory bodies, with a copy of the current 
protocol (V.6.0 currently) available for download from 
the study website. Amendments to date are listed in 
online supplementary appendix 1.
Consent and assent
Written consent for taking part in the trial will be received 
by a researcher from the parent or guardian of the partic-
ipant at their baseline appointment. For children approx-
imately 7 years and older, the option of providing assent 
will be offered alongside parental consent (see online 
supplementary appendix 2).
Confidentiality and access to data
The database and randomisation system will protect 
patient information in line with the data protection legis-
lation. Trial staff will ensure that participants’ anonymity 
is maintained through protective and secure handling 
and storage of patient information at the lead centre. The 
chief investigator will have access to and act as custodian 
of the full data set.
Ancillary and post-trial care
After the 16 week primary outcome period, partici-
pants will be free to change their emollient if they wish. 
Conversely, they will be able to continue with their allo-
cated emollient after they have completed follow- up.
dissemination and data sharing
A series of stakeholder meetings will raise study aware-
ness among and share progress and findings with poli-
cymakers, voluntary groups, clinicians, patients, families. 
Study progress, outputs and a summary of findings will be 
made available via a study website and Twitter account; 
and summaries distributed to participating families and 
GP surgeries. Findings will be submitted for presentation 
at conferences and written up for publication in a peer- 
reviewed journal(s), which may include integration of the 
quantitative and qualitative findings. The International 
Committee of Medical Journal Editors has criteria for 
authorship will be observed and no professional writers 
will be employed.
No later than 3 years after the completion of the study, 
we will deposit a de- identified data set in an appropriate 
data archive.
dIsCussIon
Factors that may influence patient preference for different 
types of emollient include disease severity, body site, 
cosmetic acceptability of the product, season/climate and 
packaging.29 Cultural factors may also influence choice 
and use.30 NICE recommends patients try different emol-
lients in the clinic before choosing.5 This approach is not 
practical in primary care, and even in specialist settings 
the range of emollients available to try can be arbitrary — 
restricted by local formularies and influenced of pharma-
ceutical companies. Therefore, most patients consulting 
in primary care are unaware of differences between emol-
lients; and many primary care clinicians will be unable to 
advise on grounds other than consistency or simple unit 
cost.
Some emollients are decades old and it has not been 
in the interest of manufacturers to submit their products 
in a head- to- head comparison with others in a clinical 
trial. In BEE, we are independently evaluating in a prag-
matic trial, using a validated patient- reported primary 
outcome, the effectiveness of the four types of emol-
lients commonly prescribed for children with eczema. In 
accordance with the recommendations of Harmonising 
Outcome Measures in Eczema, POEM and EASI will be 
used to measure patient- reported symptoms and clinical 
signs, respectively.31
Participants are unmasked, so knowing which emol-
lient they’re using may bias assessment of emollient effec-
tiveness. However, we have chosen a patient- reported 
outcome as the primary outcome because symptoms of 
eczema are more important to families of than objective 
measures which are based on skin appearance.11 We will 
minimise the potential for performance bias by ensuring 
that at the point of consent parents are willing to use any 
of the four emollients for the first 16 weeks. We will also 
measure at baseline parent opinion regarding the four 
different study emollients, and in a subgroup analysis 
explore whether reported effectiveness is linked to high/
low prior expectations of effectiveness. The collection 
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of an objective measure of eczema severity (EASI) by a 
masked researcher as a secondary outcome allows us to 
examine outcomes in relation to signs of eczema. Subject 
to additional funding, we plan to undertake a full econom-
ical evaluation to determine the cost- effectiveness of the 
four emollient types.
Recruitment started in January 2018 and follow- up of the 
last participant is scheduled by February 2021. Findings 
from the BEE study, comparing the clinical effectiveness 
and acceptability of commonly used different emollients, 
will provide evidence on which clinicians and carers/
patients can decide which emollient to try first. Our aim 
is not to reduce choice, but to reduce uncertainty and 
the consequences of ‘trial and error’ prescribing. Smarter 
prescribing will help prescribers and carers gain ‘control’ 
over the eczema more quickly, reduce frustration and 
inconvenience for families and potentially produce cost 
savings to the NHS through cost- effective prescribing and 
fewer repeat consultations to change emollients.
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